Hopewell Therapeutics, a Woburn, MA-based biotechnology company with a differentiated lipid nanoparticle platform harnessing unique ionizable lipid chemistry, announced a Seed Financing of up to $25m.
The round has been supported by Mass Ave Capital, 5Y Capital, HIKE Capital, BOPU Capital, IMO Capital and WS Investments.
The funds will enable the company to advance the development of genomic medicines based on its differentiated ttLNP platform through both internal pipeline programs and external partnerships.
Established in 2021 with Scientific Founder Qiaobing Xu, Ph.D., Professor of Biomedical Engineering at Tufts University and Chief Technology Officer at Hopewell, and led by Louis Brenner, M.D., an experienced biotech industry executive, who serves as President and Chief Executive Officer, Hopewell Therapeutics is discovering, synthesizing, and developing the next generation of tissue-targeted lipid nanoparticles (ttLNPs) to bring genomic medicines to patients. The company is designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. Hopewell has built an intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry leading companies. Hopewell is developing its own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of its ttLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases, and neurological disorders.
The company holds exclusive licenses to its ttLNP intellectual property estate from Tufts University for use in a broad field of clinical and commercial applications and has established multiple research relationships with leading industry partners.
FinSMEs
07/06/2023